Latest Breaking News On - Glenn prestwich - Page 1 : comparemela.com
WSU Health Sciences incubator, sp3nw, receives $750,000 grant for pandemic response – WSU Insider
wsu.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsu.edu Daily Mail and Mail on Sunday newspapers.
Sp
3nw’s proposal was chosen for its unique framework to create a flexible infrastructure for resilient entrepreneurship, referred to as FIRE, which consists of support programs that spur regional economic development in eastern Washington and North Idaho.
“We are thrilled to be chosen as a recipient in the Department of Commerce/Economic Development Administration’s competitive SPRINT challenge. This validates the sp
3nw program and its delivery of innovative life science to the region,” said Glenn Prestwich, who is both the principal investigator for the project and the director for sp
3nw.
Continued Prestwich, “Our proposal was unique in that it matches startups in the area with executive advisors and interns to help expedite go-to-market actions. The project will provide wrap-around services to startups including marketing, bookkeeping and business research. As we talk to life sciences entrepreneurs, these are often the services they lack capacity to carry out.”
(0) HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005119/en/
HTL s campus is located in Paris, France. HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable dis
Posted on 524
Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC
TM) platform, announced today the members of its strategic advisory board, which bring a range of expertise to the company including corporate strategy, clinical development, cellular biology, and cancer therapeutics.
“Shasqi has made important progress during the last year with the initiation of our phase 1 clinical trial of SQ3370 and the advancement of our CAPAC drug development platform we’re preparing for the next phase of our growth,” said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi. “We’ve deliberately selected and cultivated a team of strategic advisors with the skills, expertise and experience to help us navigate through the opportunities ahead of us and, ultimately, position us to benefit as many peop
vimarsana © 2020. All Rights Reserved.